Deutsches Herzzentrum München & 1. Medizinische Klinik, Technische Universität München, Munich, Germany.
Platelets. 2012;23(5):395-8. doi: 10.3109/09537104.2012.691189. Epub 2012 Jun 6.
Little is known about the antiplatelet action of the thienopyridines, clopidogrel and prasugrel, as well as the non-thienopyridine, ticagrelor, in patients suffering from ST-elevation myocardial infarction (STEMI) complicated by cardiogenic shock since systematic comparisons of these antiplatelet agents in this devastating condition are limited so far. This is a report of a patient with STEMI undergoing urgent PCI in cardiogenic shock followed by repeated angioplasty after suffering early stent thrombosis (ST) who showed dual thienopyridine treatment failure of clopidogrel and prasugrel, which was successfully overcome by switching the patient to the non-thienopyridine derivative ticagrelor.
关于噻吩吡啶类药物（氯吡格雷和普拉格雷）以及非噻吩吡啶类药物（替格瑞洛）在 ST 段抬高型心肌梗死（STEMI）合并心源性休克患者中的抗血小板作用知之甚少，因为到目前为止，还没有对这些抗血小板药物在这种严重情况下进行系统比较。这是一例 STEMI 患者在发生心源性休克后接受紧急 PCI，随后因早期支架血栓形成（ST）而反复进行血管成形术的病例报告。该患者对氯吡格雷和普拉格雷的双重噻吩吡啶治疗失败，随后改用非噻吩吡啶衍生物替格瑞洛成功克服。
